Loading…
Agreement includes upfront payment and potential milestone payments.
Servier and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) announced on March 19, 2025, a global licensing agreement for BDTX-4933, a targeted oncology therapy. The agreement includes an upfront payment of $70 million and potential development and commercial sales milestone payments of up to $710 million, along with tiered royalties based on global net sales.
The agreement grants Servier exclusive global rights to develop and commercialize BDTX-4933. Black Diamond Therapeutics will receive an upfront payment of $70 million and is eligible for up to $710 million in milestone payments. Additionally, Black Diamond Therapeutics will receive tiered royalties on global net sales of the product.
Black Diamond Therapeutics has a free float of 39,325,800 shares and 56,975,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.